Scientific Advisory Council

  • Ira Dunkel, MD, Scientific Advisory Council Coordinator
  • David Lyden, MD, PhD
  • Maryam Fouladi, MD
  • Nada Jabado, MD, PhD
  • Oren Becher, MD
  • Mark Kieran, MD, PhD

Brain Tumor Research

  • Regression of Glioblastoma after Chimeric Antigen Receptor T-cell Therapy. December 29, 2016, Brown CE. Alizabeth D. StarrRet al, N Engl J Med 2016; 375: 2561-2569
  • City of Hope Researchers Achieve Remission using CAR-T cell therapy for Aggressive Brain Tumors Dec 28, 2016- Contract City of Hope, 626-409-9367 Denise Heady, or 626-218-6279, David Caovette
  • The PD-1 checkpoint pathway-Nov 3, 2016, V.A-Boussiotis etal. N Engl J Med 2016. 375; 1767- 1778

Funded Studies

Dana-Farber Cancer Institute: Mark Kieran, M.D., Ph.D. “Discovering new treatments for Malignant Supratentorial High-Grade Gliomas (HGG) and Diffuse Intrinsic Pontine Glioma (DIPG)”

This study consists of developing new target and immune therapies for pediatric gliomas. The drugs to be developed will target tumor cell aberrations including the histone mutation H3.3K27M and abnormalities in the PDGFR, EFGR, and PI3K cell signaling cascades. The drugs will also be screened for their capacities to penetrate the blood-brain barrier using a novel method recently developed at DFCI. This study is meant to provide preclinical models, which can lead to clinical trials of the drugs developed.